Healthsouth Corp (HLS) 40.81 $HLS HealthSouth And

New Post Public Reply Private Reply Replies (0) Message Board

Sep 5, 2016 at 9:11 AM

Healthsouth Corp (HLS) 40.81 $HLS

HealthSouth And Tidelands Health Announce Joint Venture To Operate Inpatient Rehabilitation Hospitals In South Carolina
PR Newswire - Mon Aug 29, 6:00AM CDT
HealthSouth Corporation (NYSE: HLS) and Tidelands Health have formed a joint venture to own and operate Tidelands' existing inpatient rehabilitation hospital. The hospital is located at 4070 Highway 17 Bypass South in Murrells Inlet, South Carolina, on the campus of Tidelands Waccamaw Community Hospital. The joint venture expects to operate 29 inpatient rehabilitation beds at this location.
HLS: 40.81 (+0.61)

HealthSouth To Present At Investor Conferences In September
PR Newswire - Wed Aug 17, 7:00AM CDT
HealthSouth Corporation (NYSE: HLS) today announced it will participate in the following investor conferences in September 2016:
HLS: 40.81 (+0.61)

$310-Million Settlement Awarded in Fraud Class Action Against Caremark and AIG
PR Newswire - Tue Aug 16, 8:49AM CDT
An Alabama Circuit Court Judge granted final approval on Monday to a $310-million class action settlement that seeks to rectify a fraud committed on more than 20,000 individuals, entities and pension plans who owned stock in MedPartners, Inc., in the late 1990s.
HLS: 40.81 (+0.61)

PRIUM Executives to Present in Three Sessions at WCI's WCEC
BusinessWire - Tue Aug 16, 5:02AM CDT
PRIUM's Senior Vice President and Mark Pew, the Rx Professor, and President Michael Gavin will participate in three sessions at the Workers' Compensation Institute's Annual Workers' Compensation Educational Conference.
HLS: 40.81 (+0.61)

HealthSouth Shares Up 19.2% Since SmarTrend's Buy Recommendation (HLS)
Comtex SmarTrend(R) - Tue Aug 02, 1:30AM CDT
SmarTrend identified an Uptrend for HealthSouth (NYSE:HLS) on February 25th, 2016 at $35.28. In approximately 5 months, HealthSouth has returned 19.21% as of today's recent price of $42.05.
HLS: 40.81 (+0.61)

After Yesterday's Rally of 7.92% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jul 29, 2:26PM CDT
HealthSouth (NYSE:HLS) traded in a range yesterday that spanned from a low of $40.57 to a high of $43.38. Yesterday, the shares gained 7.9%, which took the trading range above the 3-day high of $41.14 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HLS: 40.81 (+0.61)

HealthSouth Reports Strong Revenue, Volume, and Earnings Growth for Second Quarter 2016 and Raises Full-Year 2016 Guidance
PR Newswire - Thu Jul 28, 3:30PM CDT
HealthSouth Corporation (NYSE: HLS), one of the nation's largest providers of post-acute healthcare services, offering both facility-based and home-based post-acute services, today reported its results of operations for the second quarter ended June 30, 2016.
HLS: 40.81 (+0.61)

Top Stocks with Big Potential Catch-Up Moves
Kevin Matras - ZACKS - Tue Jul 26, 2:31PM CDT
Top Stocks with Big Potential Catch-Up Moves
CSGP: 213.05 (+2.97), CW: 91.12 (+1.00), INGN: 58.11 (+0.16), HLS: 40.81 (+0.61), PKI: 53.46 (+0.20)

How Rewarding Investors Believe These Specialized Health Services Stocks are? - AMN Healthcare Services, MEDNAX, HEALTHSOUTH, and Acadia Healthcare
PR Newswire - Tue Jun 21, 6:50AM CDT
The Healthcare sector continues to undergo fundamental shifts as the demand for innovative technologies and improved services continues to increase. Growth opportunities are present, and today Stock-Callers.com looks at four stocks in the Specialized Health Services space for assessment: AMN Healthcare Services Inc. (NYSE: AHS), MEDNAX Inc. (NYSE: MD), HEALTHSOUTH Corp. (NYSE: HLS), and Acadia Healthcare Co. Inc. (NASDAQ: ACHC). Access these stocks complimentary alerts at:
ACHC: 51.61 (+1.28), AHS: 36.25 (+0.57), HLS: 40.81 (+0.61), MD: 66.57 (+2.09)

BioScrip (BIOS): Soft Revenue Outlook & Weak Margins Linger
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 7:18AM CDT
On Jun 13, 2016, we issued an updated research report on BioScrip, Inc. (BIOS).
USPH: 64.10 (+0.98), LHCG: 35.93 (+1.03), BIOS: 2.64 (+0.07), HLS: 40.81 (+0.61)

7 Medical Stocks to Buy with Market-Beating Yields
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:50AM CDT
Medical is one of the very few sectors that generally show great resilience during volatile phases in the market.
KND: 10.74 (+0.27), ABT: 42.09 (-0.21), JNJ: 119.32 (+0.24), PFE: 34.77 (+0.09), BMY: 56.35 (-0.41), HLS: 40.81 (+0.61), DRAD: 5.26 (+0.12)

Chemed Posts Balanced Growth amid Coding Change Issues
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 5:42AM CDT
On Jun 7, 2016, we issued an updated research report on Chemed Corporation (CHE).
CHE: 137.34 (+2.39), PMC: 25.95 (+0.76), LHCG: 35.93 (+1.03), HLS: 40.81 (+0.61)

AmSurg (AMSG): Strong Q1 on Organic & Acquisition Growth
Zacks Equity Research - Zacks Investment Research - Thu May 26, 6:19AM CDT
On May 20, 2016, we issued an updated research report on Nashville, TN-based AmSurg Corp. (AMSG).
AMSG: 67.29 (+1.89), USPH: 64.10 (+0.98), LHCG: 35.93 (+1.03), HLS: 40.81 (+0.61)

HEALTHSOUTH (HLS): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:45AM CDT
HEALTHSOUTH (HLS) in the Medical-Outpatient/Home Care space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
HLS: 40.81 (+0.61)

DaVita to Expand in Orlando with Family Health Care Buyout
Zacks Equity Research - Zacks Investment Research - Mon May 23, 3:07PM CDT
DaVita Healthcare Partners (DVA) has entered into a definitive agreement to acquire Family Health Care of Central Florida to expand its presence in Orlando metro area.
PMC: 25.95 (+0.76), AFAM: 36.63 (+0.22), DVA: 64.78 (+0.59), HLS: 40.81 (+0.61)

Moving Average Crossover Alert: HEALTHSOUTH (HLS)
Zacks Equity Research - Zacks Investment Research - Mon May 23, 8:42AM CDT
HEALTHSOUTH Corp. (HLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
HLS: 40.81 (+0.61)

Quest Diagnostics (DGX) Divests Focus, Cuts Sales View
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:44AM CDT
Quest Diagnostics Inc. (DGX) has updated its outlook for 2016 following the completion of the sale of Focus Diagnostics Inc.
AFAM: 36.63 (+0.22), LHCG: 35.93 (+1.03), DGX: 83.04 (+0.68), HLS: 40.81 (+0.61)

4 GARP Stocks to Boost Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Thu May 12, 11:31AM CDT
Investors following GARP would love to invest in undervalued stocks that offer solid growth prospects too.
TJX: 77.68 (-0.05), CASY: 133.28 (+1.81), HLS: 40.81 (+0.61), SIG: 82.00 (+1.37)

HealthSouth To Participate In The UBS Global Healthcare Conference
PR Newswire - Tue May 10, 3:30PM CDT
HealthSouth Corporation (NYSE: HLS) today announced it will participate in the UBS Global Healthcare Conference in New York City, May 23-25, 2016.
HLS: 40.81 (+0.61)

The Kroger Co trade offers a 10% return in 256 days, or find similar option trades on NXP Semiconductors, Sotheby's, HEALTHSOUTH Corp., and Mylan
PR Newswire - Tue May 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for KR, NXPI, BID, HLS and MYL.
BID: 40.16 (+0.66), KR: 32.50 (+0.54), MYL: 39.97 (-1.95), NXPI: 88.15 (+0.20), HLS: 40.81 (+0.61)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Investors Gear Up for Lennar Class Action Lawsuit

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Viking Ventures: Impacts of VK2735 on Obesity Examined

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...